English

KALEIDO BIOSCIENCES, INC.

EDGAR

KLDO Annual report (10-K) · filed 2022-04-01

15 filing records in this dataset, filed from 2019-01-11 to 2022-04-01. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

488 thousand USD

2021 Q4 · USD

Exact inputs and evidence

Revenue: 1100000 USD Source
Revenue: 612000 USD Source

Operating margin

-4,036.68%

2021 Q4 · %

Exact inputs and evidence

Operating Income: -87667000 USD Source
Operating Income: -67968000 USD Source
Revenue: 1100000 USD Source
Revenue: 612000 USD Source

Operating cash flow

-17.2 million USD

2021 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -77100000 USD Source
Operating Cash Flow: -59934000 USD Source

Free cash flow

-17.6 million USD

2021 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -77100000 USD Source
Operating Cash Flow: -59934000 USD Source
Capital Expenditure: 1129000 USD Source
Capital Expenditure: 693000 USD Source

Cash and cash equivalents: 38.5 million USD 2021-12-31 Source
Exact value

38500000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 42.6 million shares 2021-12-31 Source
Exact value

42596037 shares

Reported share-count change

18.25% · 6.57 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

36022811 shares · 2020-12-31· Source
42596037 shares · 2021-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.1 million USD

2021-01-01 – 2021-12-31

Exact inputs and evidence

Revenue: 297000 USD · 2021-01-01 – 2021-03-31 Source
Revenue: 211000 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 104000 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 1100000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 612000 USD · 2021-01-01 – 2021-09-30 Source

Net income

-90.3 million USD

2021-01-01 – 2021-12-31

Exact inputs and evidence

Net income: -23042000 USD · 2021-01-01 – 2021-03-31 Source
Net income: -23889000 USD · 2021-04-01 – 2021-06-30 Source
Net income: -23085000 USD · 2021-07-01 – 2021-09-30 Source
Net income: -90300000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -70016000 USD · 2021-01-01 – 2021-09-30 Source

Operating cash flow

-77.1 million USD

2021-01-01 – 2021-12-31

Exact inputs and evidence

Operating cash flow: -23974000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -44057000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -23974000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -59934000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -44057000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -77100000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -59934000 USD · 2021-01-01 – 2021-09-30 Source

Capital expenditure

1.13 million USD

2021-01-01 – 2021-12-31

Exact inputs and evidence

Capital expenditure: 30000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 262000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 30000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 693000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 262000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 1129000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 693000 USD · 2021-01-01 – 2021-09-30 Source

Free cash flow

-78.2 million USD

2021-01-01 – 2021-12-31

Exact inputs and evidence

Operating cash flow: -23974000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -44057000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -23974000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -59934000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -44057000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -77100000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -59934000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 30000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 262000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 30000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 693000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 262000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 1129000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 693000 USD · 2021-01-01 – 2021-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-04-01.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2021-12-31
Operating income: 4 of 11 periods available· newest 2021-12-31
Net income: 4 of 11 periods available· newest 2021-12-31
Operating cash flow: 4 of 11 periods available· newest 2021-12-31
Capital expenditure: 4 of 11 periods available· newest 2021-12-31
Total assets: 2 of 11 periods available· newest 2021-12-31
Total liabilities: 2 of 11 periods available· newest 2021-12-31
Current assets: 2 of 11 periods available· newest 2021-12-31
Current liabilities: 2 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2021-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+12.8%

Prior period

USD 975,000

2020-01-01 – 2020-12-31
Current period

USD 1.1 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

1100000 − 975000 = 125000 USD

975000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
1100000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · KALEIDO BIOSCIENCES, INC. · 2021-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Year-over-year change in Revenue: 125000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#2473353 Filing: 000095017022005256 Input fundies:Revenue: 975000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1503686 Filing: 000095017022005256
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 8.7 million

Prior period

−USD 81.6 million

2020-01-01 – 2020-12-31
Current period

−USD 90.3 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-90300000 − -81600000 = -8700000 USD

-81600000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-90300000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · KALEIDO BIOSCIENCES, INC. · 2021-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Year-over-year change in Net income: -8700000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -90300000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1849493 Filing: 000095017022005256 Input fundies:NetIncome: -81600000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1850106 Filing: 000095017022005256
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 15.6 million

Prior period

−USD 61.5 million

2020-01-01 – 2020-12-31
Current period

−USD 77.1 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-77100000 − -61500000 = -15600000 USD

-61500000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-77100000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · KALEIDO BIOSCIENCES, INC. · 2021-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Year-over-year change in Operating cash flow: -15600000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -77100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1850776 Filing: 000095017022005256 Input fundies:OperatingCashFlow: -61500000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1851418 Filing: 000095017022005256
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-71.9%

Prior period

USD 4.02 million

2020-01-01 – 2020-12-31
Current period

USD 1.13 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

1129000 − 4024000 = -2895000 USD

4024000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
1129000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · KALEIDO BIOSCIENCES, INC. · 2021-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Year-over-year change in Capital expenditure: -2895000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1129000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1757900 Filing: 000095017022005256 Input fundies:CapitalExpenditure: 4024000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1759890 Filing: 000095017022005256
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 1.1 million 100% of revenue
Operating costs Derived USD 88.77 million 8,070% of revenue
Operating income −USD 87.67 million −7,970% of revenue
Tax, interest and other Derived USD 2.63 million 239% of revenue
Net income −USD 90.3 million −8,209% of revenue

Cash

Operating cash flow −USD 77.1 million −7,009% of revenue
Capital expenditure USD 1.13 million 103% of revenue
Free cash flow Derived −USD 78.23 million −7,112% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 8,190% of revenue.
2021 Operating loss: operating costs were 8,070% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	975000	79849000 Derived	-78874000	2726000 Derived	-81600000	-65524000 Derived	Source 2020-01-01 – 2020-12-31: 975000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -78874000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -81600000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -61500000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 4024000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1100000	88767000 Derived	-87667000	2633000 Derived	-90300000	-78229000 Derived	Source 2021-01-01 – 2021-12-31: 1100000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -87667000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -90300000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -77100000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1129000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.1M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	975000	Revenue: 975000 Open source
20212021-12-31	Revenue	1100000	Revenue: 1100000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

12.8% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 975000 Open source
20212021-12-31	Year over year	12.8%	Revenue: 1100000 Open source Revenue: 975000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -7,969.7% 2021

Net margin -8,209.1% 2021

Free cash flow margin -7,111.7% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-8,089.6%	Operating Income: -78874000 Open source Revenue: 975000 Open source
20212021-12-31	Operating margin	-7,969.7%	Operating Income: -87667000 Open source Revenue: 1100000 Open source
20202020-12-31	Net margin	-8,369.2%	Net Income: -81600000 Open source Revenue: 975000 Open source
20212021-12-31	Net margin	-8,209.1%	Net Income: -90300000 Open source Revenue: 1100000 Open source
20202020-12-31	Free cash flow margin	-6,720.4%	Revenue: 975000 Open source Operating Cash Flow: -61500000 Open source Capital Expenditure: 4024000 Open source
20212021-12-31	Free cash flow margin	-7,111.7%	Revenue: 1100000 Open source Operating Cash Flow: -77100000 Open source Capital Expenditure: 1129000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -77.1M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-61500000	Operating Cash Flow: -61500000 Open source
20212021-12-31	Operating cash flow	-77100000	Operating Cash Flow: -77100000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -78.2M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-65524000	Operating Cash Flow: -61500000 Open source Capital Expenditure: 4024000 Open source
20212021-12-31	Free cash flow	-78229000	Operating Cash Flow: -77100000 Open source Capital Expenditure: 1129000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

78.8% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	65.5%	Total Liabilities: 38848000 Open source Total Assets: 59344000 Open source
20212021-12-31	Liabilities / assets	78.8%	Total Liabilities: 39530000 Open source Total Assets: 50137000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.43× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	2.92×	Current Assets: 48721000 Open source Current Liabilities: 16659000 Open source
20212021-12-31	Current assets / current liabilities	1.43×	Current Assets: 42311000 Open source Current Liabilities: 29682000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 61.7 million Exact value Exact value: -61700000 USD 2018-01-01 – 2018-12-31: -61700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALEIDO BIOSCIENCES, INC. · 2018-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Net Income: -61700000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -61700000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459020007969/kldo-10k_20191231.htm#1921267 Filing: 000156459020007969 The citation records this snapshot. The page link may show a newer release later.	−USD 46.3 million Exact value Exact value: -46300000 USD 2018-01-01 – 2018-12-31: -46300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALEIDO BIOSCIENCES, INC. · 2018-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Operating Cash Flow: -46300000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -46300000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459020007969/kldo-10k_20191231.htm#1921795 Filing: 000156459020007969 The citation records this snapshot. The page link may show a newer release later.	USD 3 million Exact value Exact value: 3002000 USD 2018-01-01 – 2018-12-31: 3002000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KALEIDO BIOSCIENCES, INC. · 2018-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Capital Expenditure: 3002000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3002000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459020007969/kldo-10k_20191231.htm#1818440 Filing: 000156459020007969 The citation records this snapshot. The page link may show a newer release later.	−USD 49.3 million Calculation and evidence -46300000 − 3002000 USD Exact free cash flow: -49302000 USD 2018-01-01 – 2018-12-31: -46300000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 3002000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KALEIDO BIOSCIENCES, INC. · 2018-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Free cash flow: -49302000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -46300000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459020007969/kldo-10k_20191231.htm#1921795 Filing: 000156459020007969 Input fundies:CapitalExpenditure: 3002000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459020007969/kldo-10k_20191231.htm#1818440 Filing: 000156459020007969 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 86.3 million Exact value Exact value: -86300000 USD 2019-01-01 – 2019-12-31: -86300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALEIDO BIOSCIENCES, INC. · 2019-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Net Income: -86300000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -86300000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459021010420/kldo-10k_20201231.htm#1837885 Filing: 000156459021010420 The citation records this snapshot. The page link may show a newer release later.	−USD 75.8 million Exact value Exact value: -75800000 USD 2019-01-01 – 2019-12-31: -75800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALEIDO BIOSCIENCES, INC. · 2019-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Operating Cash Flow: -75800000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -75800000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459021010420/kldo-10k_20201231.htm#1838413 Filing: 000156459021010420 The citation records this snapshot. The page link may show a newer release later.	USD 3.59 million Exact value Exact value: 3586000 USD 2019-01-01 – 2019-12-31: 3586000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KALEIDO BIOSCIENCES, INC. · 2019-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Capital Expenditure: 3586000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3586000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459021010420/kldo-10k_20201231.htm#1744763 Filing: 000156459021010420 The citation records this snapshot. The page link may show a newer release later.	−USD 79.39 million Calculation and evidence -75800000 − 3586000 USD Exact free cash flow: -79386000 USD 2019-01-01 – 2019-12-31: -75800000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 3586000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KALEIDO BIOSCIENCES, INC. · 2019-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Free cash flow: -79386000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -75800000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459021010420/kldo-10k_20201231.htm#1838413 Filing: 000156459021010420 Input fundies:CapitalExpenditure: 3586000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000156459021010420/kldo-10k_20201231.htm#1744763 Filing: 000156459021010420 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 81.6 million Exact value Exact value: -81600000 USD 2020-01-01 – 2020-12-31: -81600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALEIDO BIOSCIENCES, INC. · 2020-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Net Income: -81600000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -81600000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1850106 Filing: 000095017022005256 The citation records this snapshot. The page link may show a newer release later.	−USD 61.5 million Exact value Exact value: -61500000 USD 2020-01-01 – 2020-12-31: -61500000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALEIDO BIOSCIENCES, INC. · 2020-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Operating Cash Flow: -61500000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61500000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1851418 Filing: 000095017022005256 The citation records this snapshot. The page link may show a newer release later.	USD 4.02 million Exact value Exact value: 4024000 USD 2020-01-01 – 2020-12-31: 4024000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KALEIDO BIOSCIENCES, INC. · 2020-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Capital Expenditure: 4024000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4024000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1759890 Filing: 000095017022005256 The citation records this snapshot. The page link may show a newer release later.	−USD 65.52 million Calculation and evidence -61500000 − 4024000 USD Exact free cash flow: -65524000 USD 2020-01-01 – 2020-12-31: -61500000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 4024000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KALEIDO BIOSCIENCES, INC. · 2020-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Free cash flow: -65524000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -61500000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1851418 Filing: 000095017022005256 Input fundies:CapitalExpenditure: 4024000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1759890 Filing: 000095017022005256 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 90.3 million Exact value Exact value: -90300000 USD 2021-01-01 – 2021-12-31: -90300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALEIDO BIOSCIENCES, INC. · 2021-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Net Income: -90300000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -90300000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1849493 Filing: 000095017022005256 The citation records this snapshot. The page link may show a newer release later.	−USD 77.1 million Exact value Exact value: -77100000 USD 2021-01-01 – 2021-12-31: -77100000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALEIDO BIOSCIENCES, INC. · 2021-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Operating Cash Flow: -77100000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -77100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1850776 Filing: 000095017022005256 The citation records this snapshot. The page link may show a newer release later.	USD 1.13 million Exact value Exact value: 1129000 USD 2021-01-01 – 2021-12-31: 1129000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KALEIDO BIOSCIENCES, INC. · 2021-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Capital Expenditure: 1129000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1129000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1757900 Filing: 000095017022005256 The citation records this snapshot. The page link may show a newer release later.	−USD 78.23 million Calculation and evidence -77100000 − 1129000 USD Exact free cash flow: -78229000 USD 2021-01-01 – 2021-12-31: -77100000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1129000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KALEIDO BIOSCIENCES, INC. · 2021-12-31 KALEIDO BIOSCIENCES, INC. (edgar:1751299) Free cash flow: -78229000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:22:46Z Snapshot: 6ed6cb1158e82f512cd959e049b5a4ee8b0159ce9b2bd564d7f561ccdfc203b0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1751299?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -77100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1850776 Filing: 000095017022005256 Input fundies:CapitalExpenditure: 1129000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1751299/000095017022005256/kldo-20211231.htm#1757900 Filing: 000095017022005256 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

15 filings · 772 latest values · 772 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001751299, 1751299, KLDO, edgar:1751299

Also known as KALEIDO BIOSCIENCES, INC., Kaleido BioSciences, Inc., Kaleido Biosciences, Inc.

KALEIDO BIOSCIENCES, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation